



**Nexia Biotechnologies Inc.**  
1,000 St. Charles Avenue, Block B  
Vaudreuil-Dorion, Québec J7V 8P5  
[www.nexiabiotech.com](http://www.nexiabiotech.com)

---

## **Nexia announces a move to the NEX board of the TSX Venture Exchange**

Montreal, Canada, May 9, 2005 — Nexia Biotechnologies Inc. (“Nexia”) (TSX: NXB), as previously disclosed in the Management Proxy Circular, announced today that Nexia is in the final stages of completing the application process to move its listing to the NEX board of the TSX Venture Exchange. The move is subject to approval by the TSX Venture Exchange. The number and nature of shares held by the shareholders will remain unchanged. The change relates to the NEX board of the TSX Venture Exchange, where Nexia’s shares will be traded on a going forward basis.

In order to maintain a listing on the Toronto Stock Exchange (“TSX”), where Nexia’s shares are being traded prior to the move to the NEX board, certain qualitative and quantitative requirements must be met. Subsequent to the completion of the sale of substantially of all of Nexia’s operating assets to PharmAthene Inc., as previously disclosed in March 2005, Nexia ceased to meet TSX listing requirements, as it will no longer be engaged in ongoing business. As a result, Nexia’s management decided to voluntarily move Nexia’s listing to the NEX board, a newly established separate board of the TSX Venture Exchange. Nexia will continue to be a reporting issuer under securities legislation in Canada following this move. Nexia’s trading symbol is expected to be NXB.H. For more information about the NEX exchange, please visit [www.tsx.com/en/nex](http://www.tsx.com/en/nex). Investors should contact their broker in order to obtain additional information on how to trade Nexia’s shares on the NEX board of the TSX Exchange.

### **ABOUT NEXIA**

For more information, please visit Nexia's website at [www.nexiabiotech.com](http://www.nexiabiotech.com) and Nexia’s continuing disclosure filings at [www.sedar.com](http://www.sedar.com).

### **FORWARD-LOOKING STATEMENT AND OTHER IMPORTANT INFORMATION**

Except for the historical information presented herein, matters discussed herein may constitute forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "believes"; "anticipates"; "intends"; "plans"; "expects"; "estimates"; or similar statements are forward-looking statements. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors. Nexia specifically disclaims any obligation to update these forward-looking statements. Nexia assumes no responsibility with respect to any information contained herein relating to any entity other than itself. Website addresses referred to herein are provided for convenience purposes only and information contained therein is not incorporated herein by reference, nor does Nexia assume any responsibility in connection therewith. For more information, please visit [www.sedar.com](http://www.sedar.com).

### **CONTACT INFORMATION**

William C. Garriock, President, CEO and Chairman of the Board  
Dejan Ristic, CFO  
450.424.8922  
[investors@nexiabiotech.com](mailto:investors@nexiabiotech.com)